Status:

UNKNOWN

Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA)

Lead Sponsor:

Medical University of Warsaw

Collaborating Sponsors:

KCRI

Conditions:

In-Stent Restenosis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The aim of the study is to compare rapamycin eluting stent and paclitaxel eluting balloon catheter in the treatment of restenosis in bare metal stent.

Detailed Description

Study aims: * Clinical efficacy evaluation of different treatment's strategies, including periprocedural and long-term endpoints defined as: death, myocardial infarction, brain stroke, necessity of r...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • at least 18 years of age
  • symptomatic restenosis in bare metal stent implanted in native coronary artery
  • angina pectoris
  • ischemia evidenced by non-invasive diagnostic tests
  • angiographically evidenced in-stent restenosis \> 50% assessed by quantitative coronary angiography (QCA)
  • vessel diameter \> 2,5 mm
  • Clinical exclusion criteria:
  • myocardial infarction within less than past 72 hours
  • heart failure with left ventricular ejection fraction (LVEF) \< 30%
  • chronic renal failure with significant impairment of glomerular filtration (creatinine \> 2 mg/dl)
  • hypersensitivity or contraindication to acetylsalicylic acid, clopidogrel, heparin, abciximab, rapamycin, paclitaxel
  • hypersensitivity to contrast
  • other diseases that may cause significant deterioration in long-term prognosis
  • acute or chronic inflammatory diseases
  • patients who are unwilling to consent for participation in the study
  • Angiographic exclusion criteria:
  • significant stenosis in left main coronary artery (LM)
  • multivessel disease qualifying for coronary artery bypass grafting (CABG)
  • anatomical localization and morphology that preclude optimal percutaneous intervention intervention's (PCI) result or intravascular ultrasound (IVUS) or optical coherence tomography performance
  • vessel diameter \< 2,5 mm
  • restenotic lesion length \> 30 mm

Exclusion

    Key Trial Info

    Start Date :

    December 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    July 1 2012

    Estimated Enrollment :

    200 Patients enrolled

    Trial Details

    Trial ID

    NCT01255956

    Start Date

    December 1 2010

    End Date

    July 1 2012

    Last Update

    January 25 2011

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Instytut Kardiologii w Warszawie-Aninie

    Warsaw, Alpejska 42, Poland, 04-628

    2

    Katedra i Klinika Kardiologii Warszawskiego Uniwersytetu Medycznego

    Warsaw, Banacha 1a, Poland, 02-097

    3

    Klinika Kardiologii z Kliniką Kardiochirurgii Uniwersyteckiego Szpitala Klinicznego w Lodzi

    Lodz, Kniaziewicza 1/5, Poland, 91-347

    4

    II Department of Cardiology Medical College Jagiellonian University University Hospital in Krakow

    Krakow, Kopernika 17, Poland, 31-500

    Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA) | DecenTrialz